MENU
RLMD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Relmada Therapeutics (RLMD) Earnings Date & Reports
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone... Show more
A.I. Advisor
published Earnings
RLMD is expected to report earnings to rise 28.55% to -14 cents per share on November 05
Q3'26
Est.
$-0.14
Q2'26
Beat
by $0.08
Q1'26
Missed
by $0.01
Q4'25
Missed
by $0.10
Q3'25
Beat
by $0.15
The last earnings report on August 06 showed earnings per share of -10 cents, beating the estimate of -18 cents. With 1.56M shares outstanding, the current market capitalization sits at 482.15M.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases
Industry Biotechnology
Profile
Details
Industry
N/A
Address
2222 Ponce de Leon Boulevard
Phone
+1 786 629-1376
Employees
17
Web
https://www.relmada.com